Over 19 years of experience in R&D

01 Drug Discovery

Chemistry Research

Synthetic Chemistry

Medicinal Chemistry

Analytical Chemistry

Full Time Equivalent(FTE)

Fee For Service(FFS)

Catalyst Screening

Enzyme Catalysis

Continuous Flow Chemical Technology

Biology Research

Structural Biology

Cell Biology

Enzymology & Molecular Interactions

Antibody Discovery

Translational Medicine

High Throughput Screening

Computational Biology & Molecular Modeling

Early Pharmacokinetics

Radiolabel ADME

02 Pharmaceutical Research

Intermediates

Active Pharmaceutical Ingredients

Route Selection

Production Process Optimization

Clinical Sample Production

Impurity Traceability & Control

Generic Drug Process Study & Filing

Innovative Drug Process Study & Filing

Pharmaceutical preparation

Consistency Evaluation

Preformulation Study

Formulation Stability Study

GMP-based Clinical Sample Production & Packaging

Pilot-scale Preparation Testing

Laboratory-scale Preparation Testing

Preparation Quality Research

Formulation Technology Research

Analytical Method Development and Quality Control

CMC Filings

03 Preclinical Research

Pharmacology & Pharmacodynamics

Tumor Models

Digestive System Disease Models

Endocrine & Metabolic Disease Models

Inflammatory & Immune Diseases Models

Neural System Disease Models

Other Disease Models

PDXO Models

Ocular Diseases Models

Cardiovascular Model

Drug Safety Evaluation

Pharmacology & Toxicology Study

Safety Pharmacology

Histopathological Study

Clinicopathological Study

Drug Safety Evaluation Basic Information

Toxicokinetics

DMPK

In Vitro ADME Assays

In Vivo Pharmacokinetic Assays

Bioanalysis

Macromolecular Drugs Bioanalysis

Micromolecular Drugs Bioanalysis

IND Filings

01 One-stop Integrated Services

Drug Discovery Platform

Pharmaceutical Research Platform

Preclinical Research Services

Chemical Drug Development

One-stop API Process R&D Department

CDMO Service Platform

Pharmaceutical Research CDMO Service Platform

Translational Medicine Platform

Botanical Drug Preclinical R&D Technology Platform

02 Innovative Drug Services

ADC R&D Service Platform

PROTAC R&D Service Platform

mRNA Vaccine Bioanalysis Platform

Non-clinical Research for Cellular Immunotherapies

Nucleic Acid Drug R&D Platform

Peptide Drug Conjugate (PDC) R&D Service Platform

Antibody R&D Service

03 Key Technical Services for Drug R&D

Cytokine and Biomarker Detection Platform

Metabolite Identification (MetID) Service Platform

Drug Forming Research Platform

Safety Assessment Lab of Process Chemistry

Flow Cytometry Technology Platform

SEND Format Conversion Platform

Process Department Solid Form Screening Platform

Green Chemistry Platform

Flow Sorting Platform

NanoString nCounter Detection Platform

Routes of Drug Administration Platform

Drug Solid-State Research Service Platform

04 Drug Efficacy Evaluation for Common Diseases

IO Pharmacodynamic Model Evaluation Platform

Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases

Rodent Cerebrovascular Disease Drug Efficacy Evaluation System

05 Advanced Preparation R&D

Inhalation drug R&D platform

Ophthalmic drug R&D platform

Skin Topical Preparation R&D Platform

06 Targeted Drugs R&D Services

STAT3-targeted Drugs R&D Service

GLP-1 New Drug R&D Service

KRAS-targeted Drugs R&D Service

07 Drug analysis platform

08 Public Services

CLIENT CENTER

Intellectual Property Protection

U.S.

Address: 50 Soldiers Field Place, Boston, MA 02135 (America)

Tel: +1(626)986-9880

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

2023-10-25Medicilon Events

Medicilon congratulated AnDiCon Biotech collaborated with Simcere Pharmaceuticals to accelerate the commercialization of a new generation of anti-influenza drug ADC189

On October 10, 2023, Simcere Pharmaceutical Group Ltd. (2096.HK) announced that they entered into a collaboration agreement with Jiaxing AnDiCon Biotech Co., Ltd. (AnDiCon) on the anti-influenza innovative drug ADC189.

Learn more

2023-09-20Medicilon Events

Medicilon's Interview: See how Dr. Chen Chen from ABM Therapeutics crosses the blood-brain barrier

Shanghai Medicilon Inc. (Medicilon) has the honor to invite Dr. Chen Chen, Founder and Chairman of ABM Therapeutics, to discuss the unique technical advantages and R&D strategies of ABM Therapeutics in developing brain-targeted drugs, as well as the inner journey and profound insights.

Medicilon 688202

RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

Shanghai Public Network Security File No. 31011502018888 | Website Map

Preclinical Research

FAQs

HomeservicesPreclinical ResearchPharmacology & PharmacodynamicsTumor ModelsOrthotopic Cancer Models

Orthotopic Cancer Models

The orthotopic cancer model assesses the interaction between tumor cells and drugs in their natural organ/microenvironment and monitors tumor growth in situ. We have a variety of mature orthotopic transplantation models available, including brain, liver, lung, tibial bone marrow cavity, and intravesical orthotopic transplantation models.

Download

Model Type

Cancer Type	Orthotopic Models	Orthotopic Models (Luc Cell Line)
Spongioblastoma	U87-MG	U87-MG-luc
Lung cancer	NCI-H1650, A549, NCI-H1975, NCI-H460 and LLC1	A549-luc, LLC1-luc and NCI-H1975-luc
Colon cancer	HCT-116 and LoVo	HT29-luc,CT26.WT-luc
Gastric cancer	Hs 746T
Pancreatic cancer	Mia-Paca 2	Mia-Paca 2-luc
Breast cancer	MDA-MB-231,HCC1954, HCC70,MDA-MB-361, MCF7, HCC1954	4T1-luc,MDA-MB-231-luc
Ovary carcinoma	SK-OV-3	SK-OV-3-luc
Prostate cancer	PC3	PC-3-luc
Kidney cancer	A498
Bladder cancer	UM-UC-3
Melanoma		B16-F10-luc
Liver cancer	H22
Osteocarcinoma
Leukemia	RL, MAVER-1, Karpas299, K562,HL-60